EA024893B9 - БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ - Google Patents
БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВInfo
- Publication number
- EA024893B9 EA024893B9 EA201370205A EA201370205A EA024893B9 EA 024893 B9 EA024893 B9 EA 024893B9 EA 201370205 A EA201370205 A EA 201370205A EA 201370205 A EA201370205 A EA 201370205A EA 024893 B9 EA024893 B9 EA 024893B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- benzo
- calcium sensing
- receptor modulators
- sensing receptor
- oxazin
- Prior art date
Links
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical class C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 title 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 title 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 abstract 2
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 abstract 2
- 229910052791 calcium Inorganic materials 0.000 abstract 2
- 239000011575 calcium Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN367KO2011 | 2011-03-18 | ||
| PCT/IB2012/051268 WO2012127388A1 (en) | 2011-03-18 | 2012-03-16 | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201370205A1 EA201370205A1 (ru) | 2014-01-30 |
| EA024893B1 EA024893B1 (ru) | 2016-10-31 |
| EA024893B9 true EA024893B9 (ru) | 2017-01-30 |
Family
ID=54192843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201370205A EA024893B9 (ru) | 2011-03-18 | 2012-03-16 | БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9464063B2 (OSRAM) |
| EP (1) | EP2686306B1 (OSRAM) |
| JP (1) | JP6033835B2 (OSRAM) |
| KR (1) | KR20140051846A (OSRAM) |
| CN (1) | CN103459377B (OSRAM) |
| AP (1) | AP2013007153A0 (OSRAM) |
| AU (1) | AU2012232706B2 (OSRAM) |
| BR (1) | BR112013023914A2 (OSRAM) |
| CA (1) | CA2829466A1 (OSRAM) |
| EA (1) | EA024893B9 (OSRAM) |
| IL (1) | IL228461A0 (OSRAM) |
| MX (1) | MX2013010670A (OSRAM) |
| PH (1) | PH12013501899A1 (OSRAM) |
| SG (1) | SG193331A1 (OSRAM) |
| WO (2) | WO2012127385A1 (OSRAM) |
| ZA (1) | ZA201306837B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102041154B1 (ko) | 2012-02-24 | 2019-11-07 | 루핀 리미티드 | 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 |
| WO2013136288A1 (en) | 2012-03-16 | 2013-09-19 | Lupin Limited | Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators |
| HK1211916A1 (en) * | 2012-08-27 | 2016-06-03 | Lupin Atlantis Holdings Sa | Arylalkylamine compounds as calcium sensing receptor modulators |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| US9493396B2 (en) | 2013-08-28 | 2016-11-15 | Lupin Atlantis Holdings Sa | Substituted naphthalene compounds as calcium sensing receptor modulators |
| EP3060563B1 (en) | 2013-10-25 | 2018-05-02 | Novartis AG | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| PL3200786T3 (pl) | 2014-10-03 | 2020-03-31 | Novartis Ag | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 |
| CN104464530B (zh) * | 2014-11-18 | 2017-08-25 | 深圳市华星光电技术有限公司 | 曲面型显示装置 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| MX394242B (es) | 2017-01-11 | 2025-03-24 | Rodin Therapeutics Inc | Inhibidores biciclicos de histona desacetilasa |
| MX2020001484A (es) | 2017-08-07 | 2020-08-20 | Rodin Therapeutics Inc | Inhibidores bicíclicos de la histona desacetilasa. |
| BR112022012663A2 (pt) | 2019-12-27 | 2022-09-06 | Lupin Ltd | Composição farmacêutica de moduladores de casr e métodos e usos da mesma |
| AU2021207775B2 (en) * | 2020-01-17 | 2025-12-11 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001090069A1 (fr) * | 2000-05-24 | 2001-11-29 | Centre National De La Recherche Scientifique (Cnrs) | Composes possedant une activite calcimimetique |
| EP1882684A1 (en) * | 2005-05-19 | 2008-01-30 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| US20100029687A1 (en) * | 2006-11-16 | 2010-02-04 | Astellas Pharma Inc. | Piperidine derivative or salt thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109880A (zh) | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| CA2527203C (en) | 2003-05-28 | 2010-08-17 | Japan Tobacco Inc. | Casr antagonist |
| CA2608194A1 (en) * | 2005-05-09 | 2006-11-16 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| CN101547922B (zh) | 2006-10-04 | 2012-06-20 | 辉瑞产品公司 | 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物 |
| AU2007318092B2 (en) * | 2006-10-26 | 2013-01-10 | Amgen Inc. | Calcium receptor modulating agents |
| BRPI0819799A2 (pt) | 2007-11-23 | 2015-05-26 | Leo Pharma As | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença |
| WO2010038895A1 (ja) | 2008-10-03 | 2010-04-08 | 味の素株式会社 | ＣａＳＲアゴニスト |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| WO2010090069A1 (ja) * | 2009-02-05 | 2010-08-12 | ヤンマー株式会社 | Ｅｇｒ装置及びこれを備えたエンジン装置 |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
-
2012
- 2012-03-16 CA CA2829466A patent/CA2829466A1/en not_active Abandoned
- 2012-03-16 EA EA201370205A patent/EA024893B9/ru not_active IP Right Cessation
- 2012-03-16 WO PCT/IB2012/051263 patent/WO2012127385A1/en not_active Ceased
- 2012-03-16 MX MX2013010670A patent/MX2013010670A/es unknown
- 2012-03-16 SG SG2013067004A patent/SG193331A1/en unknown
- 2012-03-16 AU AU2012232706A patent/AU2012232706B2/en not_active Ceased
- 2012-03-16 PH PH1/2013/501899A patent/PH12013501899A1/en unknown
- 2012-03-16 EP EP12713351.0A patent/EP2686306B1/en active Active
- 2012-03-16 KR KR1020137026964A patent/KR20140051846A/ko not_active Ceased
- 2012-03-16 WO PCT/IB2012/051268 patent/WO2012127388A1/en not_active Ceased
- 2012-03-16 US US14/005,944 patent/US9464063B2/en not_active Expired - Fee Related
- 2012-03-16 JP JP2014500512A patent/JP6033835B2/ja not_active Expired - Fee Related
- 2012-03-16 AP AP2013007153A patent/AP2013007153A0/xx unknown
- 2012-03-16 CN CN201280013968.7A patent/CN103459377B/zh not_active Expired - Fee Related
- 2012-03-16 BR BR112013023914A patent/BR112013023914A2/pt active Search and Examination
-
2013
- 2013-09-11 ZA ZA2013/06837A patent/ZA201306837B/en unknown
- 2013-09-16 IL IL228461A patent/IL228461A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001090069A1 (fr) * | 2000-05-24 | 2001-11-29 | Centre National De La Recherche Scientifique (Cnrs) | Composes possedant une activite calcimimetique |
| EP1882684A1 (en) * | 2005-05-19 | 2008-01-30 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| US20100029687A1 (en) * | 2006-11-16 | 2010-02-04 | Astellas Pharma Inc. | Piperidine derivative or salt thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US9464063B2 (en) | 2016-10-11 |
| BR112013023914A2 (pt) | 2016-12-13 |
| WO2012127388A1 (en) | 2012-09-27 |
| AU2012232706B2 (en) | 2016-12-15 |
| SG193331A1 (en) | 2013-10-30 |
| CN103459377A (zh) | 2013-12-18 |
| IL228461A0 (en) | 2013-12-31 |
| AP2013007153A0 (en) | 2013-09-30 |
| MX2013010670A (es) | 2013-12-06 |
| CN103459377B (zh) | 2016-09-07 |
| ZA201306837B (en) | 2015-05-27 |
| US20140018358A1 (en) | 2014-01-16 |
| NZ616676A (en) | 2015-09-25 |
| CA2829466A1 (en) | 2012-09-27 |
| JP2014510097A (ja) | 2014-04-24 |
| WO2012127385A1 (en) | 2012-09-27 |
| KR20140051846A (ko) | 2014-05-02 |
| PH12013501899A1 (en) | 2013-11-25 |
| EA201370205A1 (ru) | 2014-01-30 |
| EP2686306A1 (en) | 2014-01-22 |
| EA024893B1 (ru) | 2016-10-31 |
| EP2686306B1 (en) | 2017-01-04 |
| AU2012232706A1 (en) | 2013-09-26 |
| JP6033835B2 (ja) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA024893B9 (ru) | БЕНЗО[b][1,4]ОКСАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЧУВСТВИТЕЛЬНЫХ К КАЛЬЦИЮ РЕЦЕПТОРОВ | |
| UY33353A (es) | Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion | |
| WO2012093809A3 (en) | New bicyclic compound for modulating g protein-coupled receptors | |
| MY162689A (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| WO2011116356A3 (en) | Positive allosteric modulators of group ii mglurs | |
| EA201300887A1 (ru) | Модуляторы s1p | |
| IL230635A (en) | An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes | |
| UY32888A (es) | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparación y uso de las mismas | |
| EA201590951A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| MX2013012211A (es) | Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato. | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| EA201590949A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| PH12014501891A1 (en) | Substituted chroman compounds as calcium sensing receptor modulators | |
| CR20140495A (es) | 5-amino[1,4]thiazines como inhibidores de bace1 | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| ATE466854T1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
| CO6541592A2 (es) | Tiazoles biciclicos como moduladores alostericos de receptores de mglur5 | |
| DE602008002598D1 (en) | Cyclohexylderivate | |
| IN2015MN00421A (OSRAM) | ||
| EP2634182A4 (en) | PROCESS FOR THE PREPARATION OF 1,3,5-TRIOXANE | |
| EP2634183A4 (en) | PROCESS FOR THE PREPARATION OF 1,3,5-TRIOXANE | |
| WO2013005168A3 (en) | Cannabinoid receptor modulators | |
| WO2012090179A3 (en) | Isoquinoline derivatives as cannabinoid receptor modulators | |
| WO2012090177A3 (en) | Cannabinoid receptor modulators | |
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |